Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ('Alterity' or 'the Company') CEO and Chairman Mr Geoffrey Kempler will present to investors at the Finance News Network event today at 12.55pm.

The event is partnered with stockbroking firm Shaw and Partners and is expected to be attended by trustees of self- managed superannuation funds, high net-worth investors, research analysts, client advisers, and retail investors. The presentations can be accessed via the following link https://www.finnewsnetwork.com.au/page/investor-events

Mr Kempler will provide a broad overview of Alterity's investment proposition including:

  • The progress of the company's lead compound ATH434 for the treatment of Multiple System Atrophy (MSA) which has successfully completed a phase 1 clinical trial.
  • The initiation of a Natural History Study at Vanderbilt University Hospital in the US which will provide important data to inform the phase 2 clinical study.
  • The expected commercialisation pathway for ATH434.
  • The track record and experience of the commercialisation team which has successfully received FDA approval for three new drug applications in the neurodegenerative space.

END

Authorization & Additional information
 This announcement was authorized by Geoffrey Kempler, Chairman and CEO of Alterity Therapeutics Limited.

Attachments

  • Original document
  • Permalink

Disclaimer

Alterity Therapeutics Ltd. published this content on 02 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 December 2020 23:00:03 UTC